All In Biotech

Drug Trial Radar · NCT07131059

MRD-positive AML Clinical Study

MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 537 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

537

Planned (sponsor's estimate)

Start

May 11, 2024

Primary completion

May 10, 2028

Study completion Oct 30, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Conditions

  • AML, Adult

Interventions

  • IvosidenibDrug

    500mg d1-28

  • GilteritinibDrug

    120mg d1-28

  • VenetoclaxDrug

    400mg d1-21 ; 400mg d1-7; 400mg d1-28; 600mg d1-14

  • AvapritinibDrug

    200mg d1-28.

  • DaunorubicinDrug

    45mg/m2/d d1-2;

  • CytarabineDrug

    100mg/m2/d d1-5

  • IdarubicinDrug

    10mg/m2/d d1-2

  • MitoxantroneDrug

    8mg/m2/d d1-2

  • HomoharringtonineDrug

    2mg/m2/d d1-5

  • AzacitidineDrug

    75mgd/m2 d1-7.

  • RuxolitinibDrug

    20 mg twice daily, 28-day cycle

  • TrametinibDrug

    12 mg twice daily, 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. relapse-free survival rateTime frame: up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.